Cargando…

Familial non-medullary thyroid cancer: a critical review

BACKGROUND: Familial non-medullary thyroid carcinoma (FNMTC), mainly of papillary histotype (FPTC), is defined by the presence of the disease in two or more first-degree relatives in the absence of other known familial syndromes. With the increasing incidence of PTC in the recent years, the familial...

Descripción completa

Detalles Bibliográficos
Autores principales: Capezzone, M., Robenshtok, E., Cantara, S., Castagna, M. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049908/
https://www.ncbi.nlm.nih.gov/pubmed/33025555
http://dx.doi.org/10.1007/s40618-020-01435-x
_version_ 1783679507712966656
author Capezzone, M.
Robenshtok, E.
Cantara, S.
Castagna, M. G.
author_facet Capezzone, M.
Robenshtok, E.
Cantara, S.
Castagna, M. G.
author_sort Capezzone, M.
collection PubMed
description BACKGROUND: Familial non-medullary thyroid carcinoma (FNMTC), mainly of papillary histotype (FPTC), is defined by the presence of the disease in two or more first-degree relatives in the absence of other known familial syndromes. With the increasing incidence of PTC in the recent years, the familial form of the disease has also become more common than previously reported and constitutes nearly 10% of all thyroid cancers. Many aspects of FNMTC are debated, concerning both clinical and genetic aspects. Several studies reported that, in comparison with sporadic PTCs, FPTCs are more aggressive at disease presentation, while other authors reported no differences in the clinical behavior of sporadic and familial PTCs. For this reason, recent guidelines do not recommend screening of family members of patients with diagnosis of differentiated thyroid cancer (DTC). FNMTC is described as a polygenic disorder associated with multiple low- to moderate-penetrance susceptibility genes and incomplete penetrance. At the moment, the genetic factors contributing to the development of FNMTC remain poorly understood, though many putative genes have been proposed in the recent years. PURPOSE: Based on current literature and our experience with FNMTC, in this review, we critically discussed the most relevant controversies, including its definition, the genetic background and some clinical aspects as screening and treatment.
format Online
Article
Text
id pubmed-8049908
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80499082021-04-29 Familial non-medullary thyroid cancer: a critical review Capezzone, M. Robenshtok, E. Cantara, S. Castagna, M. G. J Endocrinol Invest Review BACKGROUND: Familial non-medullary thyroid carcinoma (FNMTC), mainly of papillary histotype (FPTC), is defined by the presence of the disease in two or more first-degree relatives in the absence of other known familial syndromes. With the increasing incidence of PTC in the recent years, the familial form of the disease has also become more common than previously reported and constitutes nearly 10% of all thyroid cancers. Many aspects of FNMTC are debated, concerning both clinical and genetic aspects. Several studies reported that, in comparison with sporadic PTCs, FPTCs are more aggressive at disease presentation, while other authors reported no differences in the clinical behavior of sporadic and familial PTCs. For this reason, recent guidelines do not recommend screening of family members of patients with diagnosis of differentiated thyroid cancer (DTC). FNMTC is described as a polygenic disorder associated with multiple low- to moderate-penetrance susceptibility genes and incomplete penetrance. At the moment, the genetic factors contributing to the development of FNMTC remain poorly understood, though many putative genes have been proposed in the recent years. PURPOSE: Based on current literature and our experience with FNMTC, in this review, we critically discussed the most relevant controversies, including its definition, the genetic background and some clinical aspects as screening and treatment. Springer International Publishing 2020-10-06 2021 /pmc/articles/PMC8049908/ /pubmed/33025555 http://dx.doi.org/10.1007/s40618-020-01435-x Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Capezzone, M.
Robenshtok, E.
Cantara, S.
Castagna, M. G.
Familial non-medullary thyroid cancer: a critical review
title Familial non-medullary thyroid cancer: a critical review
title_full Familial non-medullary thyroid cancer: a critical review
title_fullStr Familial non-medullary thyroid cancer: a critical review
title_full_unstemmed Familial non-medullary thyroid cancer: a critical review
title_short Familial non-medullary thyroid cancer: a critical review
title_sort familial non-medullary thyroid cancer: a critical review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049908/
https://www.ncbi.nlm.nih.gov/pubmed/33025555
http://dx.doi.org/10.1007/s40618-020-01435-x
work_keys_str_mv AT capezzonem familialnonmedullarythyroidcanceracriticalreview
AT robenshtoke familialnonmedullarythyroidcanceracriticalreview
AT cantaras familialnonmedullarythyroidcanceracriticalreview
AT castagnamg familialnonmedullarythyroidcanceracriticalreview